Electromotive Drug Administration of Mitomycin C (EMDA/MMC) versus Intravesical Immunotherapy with Bacillus Calmette-Gu érin (BCG) in Intermediate and High Risk Non Muscle Invasive Bladder Cancer
Conclusions: Our findings suggest that EMDA/MMC and BCG are safe and reproducible approaches as adjuvant treatment in NMIBC. EMDA/MMC permits to achieve a fine oncological management as adjuvant treatment in NMIBC, which is not less than that obtained with BCG.Urol Int
Source: Urologia Internationalis - Category: Urology & Nephrology Source Type: research
More News: Bladder Cancer | Cancer | Cancer & Oncology | Cystoscopy | Cytology | Databases & Libraries | Immunotherapy | Statistics | Study | Urology & Nephrology